Investors Purchase High Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) saw some unusual options trading activity on Wednesday. Traders bought 1,002 put options on the company. This is an increase of 1,791% compared to the average daily volume of 53 put options.

Institutional Trading of Maravai LifeSciences

Several institutional investors have recently made changes to their positions in the business. Barclays PLC lifted its holdings in shares of Maravai LifeSciences by 349.2% during the third quarter. Barclays PLC now owns 184,189 shares of the company's stock valued at $1,531,000 after acquiring an additional 143,184 shares during the period. Franklin Resources Inc. bought a new position in Maravai LifeSciences during the 3rd quarter valued at about $600,000. JPMorgan Chase & Co. grew its stake in Maravai LifeSciences by 1,172.4% during the third quarter. JPMorgan Chase & Co. now owns 4,050,245 shares of the company's stock worth $33,658,000 after buying an additional 3,731,924 shares during the last quarter. FNY Investment Advisers LLC increased its holdings in shares of Maravai LifeSciences by 600.0% during the fourth quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company's stock worth $38,000 after buying an additional 6,000 shares in the last quarter. Finally, SG Americas Securities LLC boosted its holdings in shares of Maravai LifeSciences by 7.3% in the 4th quarter. SG Americas Securities LLC now owns 33,046 shares of the company's stock worth $180,000 after acquiring an additional 2,239 shares in the last quarter. 50.25% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on MRVI. Bank of America dropped their price target on shares of Maravai LifeSciences from $9.00 to $8.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Morgan Stanley reduced their target price on Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating for the company in a report on Tuesday, March 25th. UBS Group lowered their price target on Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a report on Friday, March 21st. Baird R W cut shares of Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 26th. Finally, Stifel Nicolaus set a $5.00 price objective on shares of Maravai LifeSciences in a report on Friday, March 21st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $6.34.

Maravai LifeSciences Stock Performance

Shares of NASDAQ MRVI traded down $0.08 during trading hours on Tuesday, reaching $2.04. The stock had a trading volume of 1,523,189 shares, compared to its average volume of 2,353,813. The company has a market cap of $518.85 million, a price-to-earnings ratio of -1.24 and a beta of 0.19. Maravai LifeSciences has a twelve month low of $1.67 and a twelve month high of $11.56. The business's fifty day moving average is $2.23 and its two-hundred day moving average is $4.33. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.